Rockwell Medical Inc. (NASDAQ:RMTI) shares rose 5.1% during mid-day trading on Wednesday . The company traded as high as $8.06 and last traded at $8.03, with a volume of 101,735 shares changing hands. The stock had previously closed at $7.64.

RMTI has been the subject of a number of analyst reports. Morgan Stanley reissued a “sell” rating on shares of Rockwell Medical in a report on Wednesday, April 6th. Zacks Investment Research raised Rockwell Medical from a “strong sell” rating to a “hold” rating in a report on Thursday, May 5th. Three equities research analysts have rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the stock. Rockwell Medical presently has an average rating of “Hold” and an average target price of $10.17.

The firm’s market capitalization is $411.18 million. The stock’s 50-day moving average price is $8.27 and its 200-day moving average price is $7.82.

Rockwell Medical (NASDAQ:RMTI) last issued its quarterly earnings data on Tuesday, May 10th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.08) by $0.02. During the same period last year, the business earned ($0.07) EPS. The firm earned $13.63 million during the quarter, compared to the consensus estimate of $15.25 million. Rockwell Medical’s revenue was down 1.8% compared to the same quarter last year. Equities analysts predict that Rockwell Medical Inc. will post ($0.27) EPS for the current fiscal year.

Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.